While the company has yet to disclose specific pricing details or the volume of shares offered, the filing outlines a clear strategy for the capital raised. ADARx plans to channel proceeds into advancing its current pipeline, which consists of five distinct programs targeting high-stakes medical conditions including obesity, Alzheimer’s disease, and strokes. These efforts represent a significant push to transition the company's research into more advanced clinical stages. By securing a position on the Nasdaq, the firm aims to bolster its development capabilities and sustain ongoing research initiatives.